Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dendrobium refers to a genus of orchids, most notably *Dendrobium officinale*, which are utilized in Traditional Chinese Medicine (TCM) under the name Shi Hu. In therapeutic contexts, it is often formulated as "Dendrobium mixture" (DM), a patented herbal preparation. Research into DM suggests it has significant anti-inflammatory and metabolic-regulating properties, particularly in the treatment of type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). Its primary mechanism of action involves the activation of peroxisome proliferator-activated receptor gamma (PPARγ), which leads to improved insulin sensitivity, reduced blood glucose levels, and the alleviation of hepatic steatosis and inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dendrobium.